

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 January 2025 (16.01.2025)



(10) International Publication Number
WO 2025/015267 A1

(51) International Patent Classification:

A61K 31/513 (2006.01) *A61P 35/00* (2006.01)
A61K 31/7068 (2006.01) *G01N 1/00* (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/037783

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

(22) International Filing Date:

12 July 2024 (12.07.2024)

Published:

— *with international search report (Art. 21(3))*

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/513,514 13 July 2023 (13.07.2023) US

(71) Applicant: **PROCESSA PHARMACEUTICALS, INC.**

[US/US]; 7380 Coca Cola Drive, Suite 106, Hanover, Mary-
land 21076 (US).

(72) Inventors: **YOUNG, David**; c/o Processa Pharmaceuticals,

Inc., 7380 Coca Cola Drive, Suite 106, Hanover, Mary-
land 21076 (US). **BIGORA, Sian**; c/o Processa Pharma-
ceuticals, Inc., 7380 Coca Cola Drive, Suite 106, Hanover,
Maryland 21076 (US). **LEONI, Lorenzo**; Via Perdaglie 32,
CH-6527 Lodrino (CH). **ISLAM, Khalid**; Via Clemente
Maraini 11, 6900 Lugano (CH).

(74) Agent: **SCHORR, Kristel** et al.; Foley & Lardner LLP,

3000 K Street, N.W., Ste. 600, Washington, District of Co-
lumbia 20007-5109 (US).

(81) Designated States (*unless otherwise indicated, for every*

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS OF PERSONALIZING CANCER TREATMENT

(57) Abstract: The present disclosure provides, among other things, personalized methods of administering PCS6422 and capecitabine in combination, personalized methods of cancer treatment, and methods of determining the frequency of (i) PCS6422 and capecitabine or (ii) capecitabine administration in a subject.

WO 2025/015267 A1